Close this search box.

Progress in Treating HER2-Positive and Triple-Negative Breast Cancer: Hopeful, Helpful Insights from RCCA Oncologists

With more than 20 locations in New Jersey, Connecticut, Maryland, and the Washington, D.C., area, Regional Cancer Care Associates (RCCA) is home to expert, board-certified medical oncologists who specialize in treating many types of cancer. For women, knowing where to turn after a breast cancer diagnosis is crucial, especially for those with HER2-positive breast cancer or triple-negative breast cancer. These aggressive forms of the disease traditionally have had lower survival rates, but advances in medicine are starting to change this outlook for the better Here, RCCA’s oncologists provide key insights into treating HER2-positive and triple-negative breast cancer.

What Is Breast Cancer?

Breast cancer can begin in one or both breasts when abnormal cells grow out of control, forming tumors. Almost all cases occur in women, but some men also are at increased risk for breast cancer. There are several different types of breast cancer correlating with the parts of the breasts affected, such as:
  • Lobular cancer (found in the lobules)
  • Ductal cancer (found in the ducts)
  • Nipple and areola cancer
  • Stromal cancer (found in the fat and connective tissue)
  • Blood and lymph vessel cancer
  • Sarcomas and lymphomas in other breast tissues
Black and white diagram of breast cells with presence of cancer highlighted in red

Breast cancer symptoms typically are consistent for many forms of the disease, although some signs may be specific to each type. Common signs of breast cancer include:

  • Breast or nipple pain
  • Changes in breast shape or skin, including dimpling, flakiness, irritation, redness, swelling, and skin creasing
  • Changes in nipple appearance, including inversion and thicker nipple skin
  • Lump in the armpit or breast
  • Nipple discharge
  • Suspicious mammogram findings


What Is HER2-Positive Breast Cancer?

This form of breast cancer is characterized by the overproduction of human epidermal growth factor receptor 2 (HER2), a type of protein receptor controlling how cells grow and divide. Considered aggressive due to the speed of tumor growth, HER2-positive cases account for up to 20% of breast cancer diagnoses. Subtypes of HER2-positive breast cancer include:

  • (HR)-positive: Cancer is fueled by estrogen, progesterone, or a combination of both hormones. These tumors tend to grow faster, metastasize (spread throughout the body), and recur after remission.
  • (HR)-negative: Cancer growth is not driven by estrogen or progesterone. This type is more common in premenopausal women.


What Is Triple-Negative Breast Cancer?

Responsible for about 15% of breast cancer diagnoses, triple-negative breast cancer cells do not have estrogen or progesterone receptors. HER2 protein receptors usually are not present in these cases, but minuscule amounts of HER2 might be present, though not enough to warrant a positive test result. This is how the type of breast cancer gets its name, as the cells test negative for estrogen, progesterone, and HER2.

Triple-negative cells generally grow and spread faster than other types of the cancerous breast cells. After a person with breast cancer is treated and the disease goes into remission, triple-negative breast cancer is more likely than other forms of the disease to recur in the following three years. However, after five years without recurrence, it is less likely to return than some other types of breast cancer. Compared to the risk for other forms of breast cancer, the risk for triple-negative breast cancer is higher in women younger than 50 years, those of Black and Hispanic origin, obese individuals, and those with the BRCA1 or BRCA2 mutation.


Progress in Treating Aggressive Breast Cancers

Traditionally, patients with HER2-positive and triple-negative breast cancer diagnoses faced poor prognoses. According to Maurice Cairoli, MD, a board-certified oncologist at RCCA’s Moorestown, NJ, office, it all began to change for the better in 2000.

The Evolution of HER2-Positive Treatment

For those with HER2-positive breast cancer, a revolutionary drug targeting the HER2 protein, along with other treatment advances, started reversing mortality rates in ways never before seen.

Today, even in patients whose HER2-positive breast cancer resisted prior treatment, antibody-drug conjugates are continuing to improve outcomes. An emerging treatment, antibody-drug conjugates deliver targeted chemotherapy directly into cancerous cells, and they minimize damage to nearby healthy tissues.

An April 2023 study reported in The Lancet found that one antibody-drug conjugate may be effective after a different medication has become ineffective. Findings like these not only provide hope but also more treatment options for patients with HER2-positive breast cancer. While these kinds of medications can produce side effects, researchers believe antibody-drug conjugates display an encouraging benefit-risk ratio.

How Far Triple-Negative Breast Cancer Treatment Has Come

Much more is known about triple-negative breast cancer than ever before.

“We talk about these being aggressive tumors, but if these tumors don’t relapse within the first two to three years of diagnosis, it’s unlikely they’re ever going to relapse,” says RCCA’s Dr. Cairoli.

“With hormone-receptor-positive breast cancers, we can never say to our patients that they are cured. There’s always a risk of occurrence that’s ongoing for 10 to 20 years after diagnosis. That’s not true of triple-negative cancer. You can tell patients that if three years have gone by and they haven’t relapsed, they probably aren’t going to. But we have to get folks through those first two or three years.”

At the 2023 Miami Breast Cancer Conference, Priyanka Sharma, M.D., Professor of Medicine at the University of Kansas Medical Center, discussed the discovery of immune checkpoint blockades, an effective treatment for early-stage triple-negative breast cancer.

Several breast cancer trials reported positive responses in patients with triple-negative diagnoses. Dr. Sharma also noted that platinum-based chemotherapy agents “have demonstrated improvement in pathologic complete response rates.”

Researchers are constantly looking for new treatments, like combination therapies targeting metastasized breast cancer cells, which will advance the fight against breast cancer.

“There are many potential treatments for triple-negative breast cancer in the drug-development pipeline,” adds Mohammad Pazooki, MD, a board-certified oncologist at RCCA’s Hartford and Manchester offices in Connecticut.


Advances in Early Breast Cancer Detection

Routine cancer screenings are highly recommended for all individuals, as these diagnostic tests can determine the presence of the disease in its earliest stages. For women, maintaining a regular mammogram schedule is a must. Physicians may make personalized recommendations for frequency based on individual risk factors. “Unfortunately, there’s no such thing as ‘too young.’ Breast cancers can occur in patients even in their 20s,” says Dr. Cairoli.

Generally, women should receive mammograms aligning with these guidelines, which represent an amalgam of recommendations from various organizations:

  • Ages 40-54: Women should get annual mammograms.
  • Ages 55-65: Women can switch to mammograms every two years if they are at average risk. If one’s risk is elevated, annual screenings can continue.
  • Ages 65 and older: Routine mammograms should continue for women in good health who are expected to live at least 10 more years or based on a guidance from their physicians.

In addition to cancer screenings, education around self-examinations has helped women become more proactive about their breast health. By knowing how their breasts normally look and feel, as well as by regularly checking for changes and lumps, women can report concerns to their physicians right away for prompt evaluation of any potential problems.

“Monthly breast self-exams haven’t been shown to improve outcomes for the population at large, but by knowing your body, you’ll be able to alert your physician if you notice a change,” adds Dr. Cairoli.

As with all types of cancer, the earlier breast cancer is detected, the more likely treatment results will be favorable. In some cases, early detection also can expand the treatment options available to a patient.

When it comes to aggressive HER2-positive and triple-negative breast cancers, early detection with routine screening has contributed to improved survival rates.


RCCA’s Treatment Options for HER2-Positive and Triple-Negative Breast Cancers

As one of the largest networks of cancer specialists in the United States, Regional Cancer Care Associates offers the latest advances in cancer treatment. After women are diagnosed, RCCA’s board-certified medical oncologists tailor individualized treatment plans based on the type of breast cancer, its severity, and other factors, such as the patient’s age and overall health.

“It’s an exciting time in the fight against breast cancer,” says Aileen L. Chen, M.D., a board-certified oncologist at RCCA’s Freehold and Holmdel, NJ, offices. “Next-generation sequencing technology is detecting genetic mutations that we can treat with targeted therapies in many forms of the disease. This has enhanced our ability to practice ‘personalized medicine’ by customizing a patient’s treatment based on her molecular and genetic profiles.”

Whether treating HER2-positive or triple-negative breast cancer, the first course of action usually is surgery. Before the procedure, patients are started on neoadjuvant therapy, which might include chemotherapy to shrink the tumor, reduce the area requiring surgery, and possibly avoid mastectomy removal of the entire breast).

There are several types of breast cancer surgeries, including:

  • Breast-sparing surgery: These procedures leave as much of the breast intact as possible and focus only on removing the tumor, as well as nearby affected tissue and lymph nodes. Subtypes include:
    • Lumpectomy: This surgery removes the tumor and is an option for patients whose cancer has not spread beyond its point of origin.
    • Partial mastectomy: The breast cancer and some surrounding healthy tissue is removed, leaving the breast intact.
    • Segmental mastectomy: The cancer, surrounding abnormal tissues, and some lymph nodes are removed, as well as part of the chest wall if cancer is nearby.
  • Mastectomy: This is the removal of the entire breast containing the cancer; in some cases, lymph nodes also are removed. Types of mastectomy include:
    • Total mastectomy: The entire breast is removed.
    • Modified radical mastectomy: The entire breast is removed except for the pectoralis major muscle. This approach sometimes is taken when cancer has not spread beyond the breast.
  • Mastectomy with reconstruction: In addition to having a mastectomy, patients also can have their breasts reconstructed with an implant or tissue from another area of the body. If the nipple was removed, surgeons can form a nipple and add a tattoo to mimic the appearance of the areola.

After this initial phase of treatment, approaches differ depending on the type of breast cancer. A combination of medications and non-invasive modalities, such as the following, may be included in a patient’s HER2-positive or triple-negative breast cancer treatment plan:

  • Chemotherapy: Patients receive powerful drugs that attack and kill cancer cells.
  • Hormone therapy: Medications suppress the body’s ability to produce hormones that feed certain types of cancer. Alternatively, drugs can interfere with how the hormones behave.
  • Immunotherapy: This treatment strengthens the immune system’s natural response to cancer cells, helping the immune system identify and kill those cells.
  • Radiation therapy: Using high-energy rays, this approach destroys or slows the growth of cancer cells.
  • Radiosurgery: Employing high-dose, precision-focused radiation beams, this type of surgery is performed from outside the body to destroy the patient’s tumor.
  • Targeted therapy: Special drugs target cancer cells directly, disrupting the cancer’s development and ability to grow. Targeted therapy can avoid harming healthy cells by acting only on malignant cells.


Considerations for Treating HER2-Positive Breast Cancer

In treating HER2-positive breast cancer, chemotherapy often is combined with targeted therapy.

Endocrine therapy, also known as hormone therapy, may be prescribed to lower estrogen levels, as this hormone, along with progesterone, can fuel tumor growth.

In premenopausal women, selective estrogen receptor modulators (SERMs) are the class of drugs typically used for endocrine/hormone therapy. In postmenopausal women, aromatase inhibitors (AIs) typically are prescribed to block estrogen production.

Ovarian suppression also can be achieved with gonadotropin-releasing hormone (GnRH) agonists, which temporarily halt estrogen production. Some women even have their ovaries surgically removed or treated radiation, stopping hormone production.

Considerations for Treating Triple-Negative Breast Cancer

Though treatment options are more limited in triple-negative breast cancer, intensive research continues to pursue new and emerging therapies.

“The problem with triple-negative breast cancer is that we don’t have a known, specific receptor to target,” explains Deena Graham, MD., who practices at RCCA’s Hackensack and North Bergen, NJ, locations.

“Triple-negative breast cancers often present with larger tumors and multiple lymph nodes involved, and they may be more aggressive. Some triple-negative cancers don’t respond well to treatment, but others do,” Dr. Graham notes.

Chemotherapy may be given before or after surgery to destroy cancer cells and shrink tumors. Poly ADP-ribose polymerase (PARP) inhibitor drugs, which target DNA damage in cancerous cells, may be administered in conjunction with other treatments for advanced triple-negative breast cancer marked by BRCA gene mutations.

Radiation therapy sometimes follows surgery, delivering high-energy X-rays to destroy any remaining cancer cells. Additionally, immunotherapy can help boost the patient’s immune system to fight breast cancer more effectively.

Breast cancer clinical trials also are available for patients with triple-negative cases. Clinical trials provide patients with access to the latest approaches to enhancing care and outcomes.

“I always recommend clinical trials for women who are diagnosed with aggressive forms of breast cancer,” adds Dr. Graham. “We can potentially make your treatment even better.”


Learn More About HER2-Positive and Triple-Negative Breast Cancer Treatment at RCCA

At Regional Cancer Care Associates, Drs. Cairoli, Chen, Graham, and Pazooki are joined by more than 80 other cancer specialists. The team treats patients at numerous community-based cancer care centers across New Jersey, Connecticut, Maryland, and the Washington, D.C., area.

Each year, RCCA treats more than 22,000 new patients and provides care to more than 225,000 established patients. Working collaboratively with patients’ other physicians, RCCA offers the latest in innovative treatments, from immunotherapy and targeted therapy to clinical trials.

In addition to treating solid tumors, blood-based cancers, and benign blood disorders like anemia, RCCA also provides infusion services. These intravenously administer medications to treat a variety of non-oncologic conditions, including multiple sclerosis, Crohn’s disease, asthma, and rheumatoid arthritis.

For more information about HER2-positive and triple-negative breast cancer treatment, contact RCCA today. Patients who have been diagnosed with cancer and are seeking state-of-the-art care can request an appointment at any of RCCA’s more than 20 locations in New Jersey, Connecticut, Maryland, and the Washington, D.C., area.

we are here for you

For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.


Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.